On Monday, Arbutus Biopharma Corp (NASDAQ: ABUS) was 5.10% up from the session before settling in for the closing price of $4.71. A 52-week range for ABUS has been $2.70 – $5.10.
Annual sales at Healthcare sector company grew by 33.46% over the past five years. When this article was written, the company’s average yearly earnings per share was at 53.03%. With a float of $150.34 million, this company’s outstanding shares have now reached $191.95 million.
Arbutus Biopharma Corp (ABUS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arbutus Biopharma Corp stocks. The insider ownership of Arbutus Biopharma Corp is 21.83%, while institutional ownership is 61.63%. The most recent insider transaction that took place on Apr 21 ’25, was worth 804,850. Before that another transaction happened on Apr 15 ’25, when Company’s Director proposed sale 53,114 for $3.20, making the entire transaction worth $170,098.
Arbutus Biopharma Corp (ABUS) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.1 earnings per share (EPS) during the time that was better than consensus figure (set at -0.12) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 53.03% per share during the next fiscal year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
You can see what Arbutus Biopharma Corp (ABUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 18.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 65.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.17 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ: ABUS) saw its 5-day average volume 1.37 million, a positive change from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 85.56%.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 92.13%, which indicates a significant increase from 87.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.46, while its 200-day Moving Average is $3.74. Nevertheless, the first resistance level for the watch stands at $5.11 in the near term. At $5.26, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.46. If the price goes on to break the first support level at $4.76, it is likely to go to the next support level at $4.56. Assuming the price breaks the second support level, the third support level stands at $4.41.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
There are 192,324K outstanding shares of the company, which has a market capitalization of 952.00 million. As of now, sales total 6,170 K while income totals -69,920 K. Its latest quarter income was 530 K while its last quarter net income were -7,740 K.
